Asunercept
- Generic Name
- Asunercept
- Drug Type
- Biotech
- CAS Number
- 1450882-18-4
- Unique Ingredient Identifier
- F333OQQ9UV
- Background
Asunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
Phase 2 Study of CAN008 in Subjects With GBM
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-12
- Lead Sponsor
- CANbridge Life Sciences Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT05447195
- Locations
- 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)
- Conditions
- COVID-19
- Interventions
- Other: Best standard of careDrug: non-RAS blocking antihypertensivesDrug: Thromboprophylaxis
- First Posted Date
- 2020-04-17
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 500
- Registration Number
- NCT04351724
- Locations
- 🇦🇹
Medical University of Innsbruck, Innsbruck, Tirol, Austria
🇦🇹Wilhelminenspital, Vienna, Austria
🇦🇹SMZ Ost Donauspital, Vienna, Austria
To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2018-11-19
- Lead Sponsor
- CANbridge Life Sciences Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03746288
NCT Neuro Master Match - N²M² (NOA-20)
- Conditions
- Glioblastoma, Adult
- Interventions
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- University Hospital Heidelberg
- Target Recruit Count
- 228
- Registration Number
- NCT03158389
- Locations
- 🇩🇪
University Hospital Mainz, Neurosurgery, Mainz, Germany
🇩🇪University Hospital Heidelberg, Neurology Clinic, Heidelberg, Germany
🇩🇪University Hospital Frankfurt, Neurooncology, Frankfurt am Main, Germany
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme
- First Posted Date
- 2016-08-03
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- CANbridge Life Sciences Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT02853565
- Locations
- 🇨🇳
Chang Gung Memorial Hospital, Linkou, Taipei, Taiwan
🇨🇳National Taiwan University Hospital, Taipei, Taiwan
APG101 in Glioblastoma
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2015-06-16
- Lead Sponsor
- Apogenix GmbH
- Target Recruit Count
- 84
- Registration Number
- NCT01071837
- Locations
- 🇩🇪
Universitätsklinik Heidelberg, Abteilung Neuroonkologie, Heidelberg, Germany
🇩🇪Universitätsklinikum Tuebingen, Strahlenonkologie, Tuebingen, Germany
🇩🇪Charite Universitätsmedizin Berlin, Klinik für Neurochirugie, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.